1
|
Bendi A, Taruna, Rajni, Kataria S, Singh L, Kennedy JF, Supuran CT, Raghav N. Chemistry of heterocycles as carbonic anhydrase inhibitors: A pathway to novel research in medicinal chemistry review. Arch Pharm (Weinheim) 2024:e2400073. [PMID: 38683875 DOI: 10.1002/ardp.202400073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 03/12/2024] [Accepted: 03/14/2024] [Indexed: 05/02/2024]
Abstract
Nowadays, the scientific community has focused on dealing with different kinds of diseases by exploring the chemistry of various heterocycles as novel drugs. In this connection, medicinal chemists identified carbonic anhydrases (CA) as one of the biologically active targets for curing various diseases. The widespread distribution of these enzymes and the high degree of homology shared by the different isoforms offer substantial challenges to discovering potential drugs. Medicinal and synthetic organic chemists have been continuously involved in developing CA inhibitors. This review explored the chemistry of different heterocycles as CA inhibitors using the last 11 years of published research work. It provides a pathway for young researchers to further explore the chemistry of a variety of synthetic as well as natural heterocycles as CA inhibitors.
Collapse
Affiliation(s)
- Anjaneyulu Bendi
- Department of Chemistry, Presidency University, Bengaluru, Karnataka, India
| | - Taruna
- Department of Chemistry, Faculty of Science, SGT University, Gurugram, Haryana, India
| | - Rajni
- Department of Chemistry, Faculty of Science, SGT University, Gurugram, Haryana, India
| | - Sweety Kataria
- Department of Chemistry, Faculty of Science, SGT University, Gurugram, Haryana, India
| | - Lakhwinder Singh
- Department of Chemistry, Faculty of Science, SGT University, Gurugram, Haryana, India
| | | | - Claudiu T Supuran
- Neurofarba Department, Pharmaceutical and Neutraceutical Section, University of Florence, Florence, Italy
| | - Neera Raghav
- Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, India
| |
Collapse
|
2
|
Angeli A, Ferraroni M, Capasso C, Supuran CT. The dopamine D 2 receptors antagonist Veralipride inhibits carbonic anhydrases: solution and crystallographic insights on human isoforms. Chem Asian J 2024; 19:e202400067. [PMID: 38334332 DOI: 10.1002/asia.202400067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 02/02/2024] [Accepted: 02/05/2024] [Indexed: 02/10/2024]
Abstract
The inhibitory effects of veralipride, a benzamide-class antipsychotic acting as dopamine D2 receptors antagonist incorporates a primary sulfonamide moiety and was investigated for its interactions with carbonic anhydrase (CA) isoforms. In vitro profiling using the stopped-flow technique revealed that veralipride exhibited potent inhibitory activity across all tested hCA isoforms, with exception of hCA III. Comparative analysis with standard inhibitors, acetazolamide (AAZ), and sulpiride, provided insights for understanding the relative efficacy of veralipride as CA inhibitor. The study reports the X-ray crystal structure analysis of the veralipride adduct with three human (h) isoforms, hCA I, II, and CA XII mimic, allowing the understanding of the molecular interactions rationalizing its inhibitory effects against each isoform. These findings contribute to our understanding of veralipride pharmacological properties and for the design of structural analogs endowed with polypharmacological properties.
Collapse
Affiliation(s)
- Andrea Angeli
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy
| | - Marta Ferraroni
- Department of Chemistry "Ugo Schiff", University of Florence, Via della Lastruccia 3-13, I-50019, Sesto Fiorentino, Florence, Italy
| | | | - Claudiu T Supuran
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy
| |
Collapse
|
3
|
Sobati M, Abdoli M, Angeli A, Bonardi A, Ferraroni M, Supuran CT, Žalubovskis R. Sulfonamide-incorporated bis(α-aminophosphonates) as promising carbonic anhydrase inhibitors: Design, synthesis, biological evaluation, and X-ray crystallographic studies. Arch Pharm (Weinheim) 2024:e2400038. [PMID: 38498884 DOI: 10.1002/ardp.202400038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 02/15/2024] [Accepted: 02/20/2024] [Indexed: 03/20/2024]
Abstract
A novel series of sulfonamide-incorporated bis(α-aminophosphonates) acting as effective carbonic anhydrase (CA, EC 4.2.1.1) inhibitors is reported. The synthesized bivalent ligands were tested against five human (h) isoforms, hCA I, hCA II, hCA VII, hCA IX, and hCA XIII. Such derivatives showed high activity and selectivity against the cancer-related, membrane-bound isoform hCA IX, and among them, compound 5h, tetraisopropyl (1,3-phenylenebis{[(4-sulfamoylphenyl)amino]methylene})bis(phosphonate) showed a KI of 15.1 nM, being highly selective against this isoform over all other investigated ones (hCA I/IX = 42; hCA II/IX = 6, hCA VII/IX = 3, hCA XIII/IX = 5). Therefore, compound 5h could be a potential lead for the development of selective anticancer agents. The newly developed sulfonamides were also found effective inhibitors against the cytosolic hCA XIII isoform. Compound 5i displayed the best inhibition against this isoform with a KI of 17.2 nM, equal to that of the well-known inhibitor acetazolamide (AAZ), but significantly more selective over all other tested isoforms (hCA I/XIII = 239; hCA II/XIII = 23, hCA VII/XIII = 2, hCA IX/XIII = 3) compared to AAZ.
Collapse
Affiliation(s)
- Marjan Sobati
- Institute of Chemistry and Chemical Technology, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia
| | - Morteza Abdoli
- Institute of Chemistry and Chemical Technology, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia
| | - Andrea Angeli
- Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Florence, Italy
| | - Alessandro Bonardi
- Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Florence, Italy
| | - Marta Ferraroni
- Dipartimento di Chimica "Ugo Schiff", University of Florence, Florence, Italy
| | - Claudiu T Supuran
- Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Florence, Italy
| | - Raivis Žalubovskis
- Institute of Chemistry and Chemical Technology, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia
- Latvian Institute of Organic Synthesis, Riga, Latvia
| |
Collapse
|
4
|
Angeli A, Chelli I, Lucarini L, Sgambellone S, Marri S, Villano S, Ferraroni M, De Luca V, Capasso C, Carta F, Supuran CT. Novel Carbonic Anhydrase Inhibitors with Dual-Tail Core Sulfonamide Show Potent and Lasting Effects for Glaucoma Therapy. J Med Chem 2024; 67:3066-3089. [PMID: 38266245 DOI: 10.1021/acs.jmedchem.3c02254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Abstract
Glaucoma, a leading cause of irreversible vision loss worldwide, is characterized by elevated intraocular pressure (IOP), a well-established risk factor across all its forms. We present the design and synthesis of 39 novel carbonic anhydrase inhibitors by a dual-tailed approach, strategically crafted to interact with distinct hydrophobic and hydrophilic pockets of CA active sites. The series was investigated against the CA isoforms implicated in glaucoma (hCA II, hCA IV, and hCA XII), and the X-ray crystal structures of compounds 25a, 25f, and 26a with CA II, along with 14b in complex with a hCA XII mimic, were determined. Selected compounds (14a, 25a, and 26a) underwent evaluation for their ability to reduce IOP in rabbits with ocular hypertension. Derivative 26a showed significant potency and sustained IOP-lowering effects, surpassing the efficacy of the drugs dorzolamide and bimatoprost. This positions compound 26a as a promising candidate for the development of a novel anti-glaucoma medication.
Collapse
Affiliation(s)
- Andrea Angeli
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy
| | - Irene Chelli
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy
| | - Laura Lucarini
- NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, 50139 Florence, Italy
| | - Silvia Sgambellone
- NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, 50139 Florence, Italy
| | - Silvia Marri
- NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, 50139 Florence, Italy
| | - Serafina Villano
- NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, 50139 Florence, Italy
| | - Marta Ferraroni
- Department of Chemistry "Ugo Schiff", University of Florence, Via della Lastruccia 3-13, 50019 Florence, Italy
| | - Viviana De Luca
- Istituto di Bioscienze e Biorisorse, CNR, 80131 Naples, Italy
| | | | - Fabrizio Carta
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy
| | - Claudiu T Supuran
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy
| |
Collapse
|
5
|
Al-Matarneh CM, Pinteala M, Nicolescu A, Silion M, Mocci F, Puf R, Angeli A, Ferraroni M, Supuran CT, Zara S, Carradori S, Paoletti N, Bonardi A, Gratteri P. Synthetic Approaches to Novel Human Carbonic Anhydrase Isoform Inhibitors Based on Pyrrol-2-one Moiety. J Med Chem 2024; 67:3018-3038. [PMID: 38301036 PMCID: PMC10895679 DOI: 10.1021/acs.jmedchem.3c02190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 01/10/2024] [Accepted: 01/11/2024] [Indexed: 02/03/2024]
Abstract
New dihydro-pyrrol-2-one compounds, featuring dual sulfonamide groups, were synthesized through a one-pot, three-component approach utilizing trifluoroacetic acid as a catalyst. Computational analysis using density functional theory (DFT) and condensed Fukui function explored the structure-reactivity relationship. Evaluation against human carbonic anhydrase isoforms (hCA I, II, IX, XII) revealed potent inhibition. The widely expressed cytosolic hCA I was inhibited across a range of concentrations (KI 3.9-870.9 nM). hCA II, also cytosolic, exhibited good inhibition as well. Notably, all compounds effectively inhibited tumor-associated hCA IX (KI 1.9-211.2 nM) and hCA XII (low nanomolar). Biological assessments on MCF7 cancer cells highlighted the compounds' ability, in conjunction with doxorubicin, to significantly impact tumor cell viability. These findings underscore the potential therapeutic relevance of the synthesized compounds in cancer treatment.
Collapse
Affiliation(s)
- Cristina M. Al-Matarneh
- Center
of Advanced Research in Bionanoconjugates and Biopolymers, “Petru Poni” Institute of Macromolecular
Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi 700487, Romania
- Research
Institute of the University of Bucharest-ICUB, 90 Sos. Panduri, 050663 Bucharest, Romania
| | - Mariana Pinteala
- Center
of Advanced Research in Bionanoconjugates and Biopolymers, “Petru Poni” Institute of Macromolecular
Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi 700487, Romania
| | - Alina Nicolescu
- NMR
Laboratory ”Petru Poni” Institute of Macromolecular
Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi 700487, Romania
| | - Mihaela Silion
- Physics
of Polymers and Polymeric Materials Department, “Petru Poni” Institute of Macromolecular Chemistry, 41A Grigore Ghica Voda Alley, 700487 Iasi, Romania
| | - Francesca Mocci
- Department
of Chemical and Geological Sciences, University
of Cagliari, 09124 Cagliari, Italy
| | - Razvan Puf
- Center
of Advanced Research in Bionanoconjugates and Biopolymers, “Petru Poni” Institute of Macromolecular
Chemistry of Romanian Academy, 41A Grigore Ghica Voda Alley, Iasi 700487, Romania
| | - Andrea Angeli
- Sezione di
Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Marta Ferraroni
- Dipartimento
di Chimica “Ugo Schiff”, University
of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino, Florence Italy
| | - Claudiu T. Supuran
- Sezione di
Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Susi Zara
- Department
of Pharmacy, “G. d’Annunzio”
University of Chieti-Pescara, via dei Vestini 31, 66100 Chieti, Italy
| | - Simone Carradori
- Department
of Pharmacy, “G. d’Annunzio”
University of Chieti-Pescara, via dei Vestini 31, 66100 Chieti, Italy
| | - Niccolò Paoletti
- Department
of Chemical and Geological Sciences, University
of Cagliari, 09124 Cagliari, Italy
- Sezione di
Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Alessandro Bonardi
- Sezione di
Scienze Farmaceutiche, NeuroFarba Department, Universita degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
- NEUROFARBA
Department, Pharmaceutical and Nutraceutical Section, Laboratory of
Molecular Modeling Cheminformatics & QSAR, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Firenze Italy
| | - Paola Gratteri
- NEUROFARBA
Department, Pharmaceutical and Nutraceutical Section, Laboratory of
Molecular Modeling Cheminformatics & QSAR, University of Florence, Via U. Schiff 6, 50019 Sesto Fiorentino, Firenze Italy
| |
Collapse
|
6
|
Angeli A, Micheli L, Turnaturi R, Pasquinucci L, Parenti C, Alterio V, Di Fiore A, De Simone G, Monti SM, Carta F, Di Cesare Mannelli L, Ghelardini C, Supuran CT. Discovery of a novel series of potent carbonic anhydrase inhibitors with selective affinity for μ Opioid receptor for Safer and long-lasting analgesia. Eur J Med Chem 2023; 260:115783. [PMID: 37678143 DOI: 10.1016/j.ejmech.2023.115783] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 08/29/2023] [Accepted: 08/30/2023] [Indexed: 09/09/2023]
Abstract
In this study, we investigated the development of dual-targeted ligands that bind to both μ-opioid receptor (MOR) and carbonic anhydrase (CA) enzymes, using fentanyl structure as a template. We synthesized and evaluated 21 novel compounds with dual-targeted affinity identifying the lead candidate compound 8, showing selective affinity for MOR and potent inhibition of several cytosolic CA isoforms. By means of repeated treatment of 3 daily administrations for 17 days, fentanyl (0.1 mg/kg, subcutaneously) led to tolerance development, pain threshold alterations and withdrawal symptoms in CD-1 mice, as well as astrocyte and microglia activation in the dorsal horn of the lumbar spinal cord. In contrast, compound 8 (0.32 mg/kg s.c.) maintained stable during days its analgesic effect at the higher dose tested with fewer withdrawal symptoms, allodynia development and glial cells activation. Our results suggest that targeting both MOR and CA enzymes can lead to the development of new class of potent analgesic agents with fewer side effects and reduced tolerance development. Further studies are needed to explore the potential mechanisms underlying these effects and to further optimize the therapeutic potential of these compounds.
Collapse
Affiliation(s)
- Andrea Angeli
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy.
| | - Laura Micheli
- Pharmacology and Toxicology Section, Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Viale G. Pieraccini, 50139, Florence, Italy
| | - Rita Turnaturi
- Department of Drug Sciences and Health, Medicinal Chemistry Section, Università degli Studi di Catania, Viale A. Doria, 6, 95125, Catania, Italy
| | - Lorella Pasquinucci
- Department of Drug Sciences and Health, Medicinal Chemistry Section, Università degli Studi di Catania, Viale A. Doria, 6, 95125, Catania, Italy
| | - Carmela Parenti
- Department of Drug Sciences and Health, Pharmacology and Toxicology Section, Università degli Studi di Catania, Viale A. Doria, 6, 95125, Catania, Italy
| | - Vincenzo Alterio
- Istituto di Biostrutture e Bioimmagini-CNR, via Pietro Castellino, 111, 80131, Naples, Italy
| | - Anna Di Fiore
- Istituto di Biostrutture e Bioimmagini-CNR, via Pietro Castellino, 111, 80131, Naples, Italy
| | - Giuseppina De Simone
- Istituto di Biostrutture e Bioimmagini-CNR, via Pietro Castellino, 111, 80131, Naples, Italy
| | - Simona Maria Monti
- Istituto di Biostrutture e Bioimmagini-CNR, via Pietro Castellino, 111, 80131, Naples, Italy
| | - Fabrizio Carta
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy
| | - Lorenzo Di Cesare Mannelli
- Pharmacology and Toxicology Section, Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Viale G. Pieraccini, 50139, Florence, Italy
| | - Carla Ghelardini
- Pharmacology and Toxicology Section, Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Viale G. Pieraccini, 50139, Florence, Italy
| | - Claudiu T Supuran
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy
| |
Collapse
|
7
|
D'Agostino I, Zara S, Carradori S, De Luca V, Capasso C, Kocken CHM, Zeeman AM, Angeli A, Carta F, Supuran CT. Antimalarial Agents Targeting Plasmodium falciparum Carbonic Anhydrase: Towards Artesunate Hybrid Compounds with Dual Mechanism of Action. ChemMedChem 2023; 18:e202300267. [PMID: 37697903 DOI: 10.1002/cmdc.202300267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 09/07/2023] [Accepted: 09/07/2023] [Indexed: 09/13/2023]
Abstract
Malaria continues to be a major public health challenge worldwide and, as part of the global effort toward malaria eradication, plasmodium carbonic anhydrases (CAs) have recently been proposed as potential targets for malaria treatment. In this study, a series of eight hybrid compounds combining the Artesunate core with a sulfonamide moiety were synthesized and evaluated for their inhibition potency against the widely expressed human (h) CAs I, II and the isoform from P. falciparum (PfCA). All derivatives demonstrated high inhibition potency against PfCA, achieving a KI value in the sub-nanomolar range (0.35 nM). Two Compounds showed a selectivity index of 4.1 and 3.1, respectively, against this protozoan isoform compared to hCA II. Three Derivatives showed no cytotoxic effects on human gingival fibroblasts at 50 μM with a high killing rate against both P. falciparum and P. knowlesi strains with IC50 in the sub-nanomolar range, providing a wide therapeutic window. Our findings suggest that these compounds may serve as promising leads for developing new antimalarial drugs and warrant further investigation, including activity against antimalarial-resistant strains, mode of action studies, and in vivo efficacy assessment in preclinical mouse models of malaria.
Collapse
Affiliation(s)
- Ilaria D'Agostino
- Department of Pharmacy "G. d'Annunzio", University of Chieti-Pescara, 66100, Chieti, Italy
| | - Susi Zara
- Department of Pharmacy "G. d'Annunzio", University of Chieti-Pescara, 66100, Chieti, Italy
| | - Simone Carradori
- Department of Pharmacy "G. d'Annunzio", University of Chieti-Pescara, 66100, Chieti, Italy
| | - Viviana De Luca
- Istituto di Bioscienze e Biorisorse CNR, 80131, Napoli, Italy
| | | | - Clemens H M Kocken
- Department of Parasitology, Biomedical Primate Research Center, 2288, Rijswijk, The Netherlands
| | - Anne-Marie Zeeman
- Department of Parasitology, Biomedical Primate Research Center, 2288, Rijswijk, The Netherlands
| | - Andrea Angeli
- Neurofarba Department, University of Florence, 50019, Sesto Fiorentino FL, Italy
| | - Fabrizio Carta
- Neurofarba Department, University of Florence, 50019, Sesto Fiorentino FL, Italy
| | - Claudiu T Supuran
- Neurofarba Department, University of Florence, 50019, Sesto Fiorentino FL, Italy
| |
Collapse
|
8
|
Vats L, Arya P, Kumar R, Giovannuzzi S, Raghav N, Supuran CT, Sharma PK. Keto-bridged dual triazole-linked benzenesulfonamides as potent carbonic anhydrase and cathepsin B inhibitors. Future Med Chem 2023; 15:1843-1863. [PMID: 37877291 DOI: 10.4155/fmc-2023-0201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2023] Open
Abstract
Background: Inhibition of human carbonic anhydrase (hCA) isoforms IX and XII with concurrent inhibition of cathepsin B is a promising approach for targeting cancers. Methods/results: 28 keto-bridged dual triazole-containing benzenesulfonamides were synthesized and tested, following the multitarget approach, for their efficacy as inhibitors of cathepsin B and hCA isoforms (I, II, IX, XII). The synthesized compounds showed excellent inhibition of CA isoforms (IX and XII) and cathepsin B. Compound 8i exhibited better and more selective inhibition of the cancer-associated isoform hCA IX as compared with acetazolamide (reference drug) and SLC-0111 (potent lead as carbonic anhydrase inhibitor). Molecular docking studies were also carried out. Conclusion: The present work gives important generalizations for the development of isoform-selective hCA inhibitors endowed with anti-cathepsin properties.
Collapse
Affiliation(s)
- Lalit Vats
- Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, 136119, India
- Department of Chemistry, Government College Bherian, Pehowa, Kurukshetra, Haryana, 136128, India
| | - Priyanka Arya
- Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, 136119, India
| | - Rajiv Kumar
- Ch. Mani Ram Godara Government College for Women, Bhodia Khera, Fatehabad, Haryana, 125050, India
| | - Simone Giovannuzzi
- Neurofarba Department, Pharmaceutical & Nutraceutical Section, University of Florence, Florence, Italy
| | - Neera Raghav
- Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, 136119, India
| | - Claudiu T Supuran
- Neurofarba Department, Pharmaceutical & Nutraceutical Section, University of Florence, Florence, Italy
| | - Pawan K Sharma
- Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, 136119, India
- Department of Chemistry, Central University of Haryana, Mahendergarh, 123031, India
| |
Collapse
|